• 0

London, UK-based Rexgenero has reached a major milestone in treating the first patient in a late-stage trial with its lead product, cell therapy REX-001. – News – PharmaTimes

Source: Rexgenero treats first patients in CLI trial – PharmaTimes

Author

PV Mayer

Dr. Perry Mayer is the Medical Director of The Mayer Institute (TMI), a center of excellence in the treatment of the diabetic foot. He received his undergraduate degree from Queen’s University, Kingston and medical degree from the Royal College of Surgeons in Ireland.

Add Comment